OPTIC

OPTIC 2000 & AUSTRALIEGAD LAUNCHED AN ORIGINAL CHALLENGE AT THE GAMERS ASSEMBLY TO RAISE PUBLIC AWARENESS OF VISUAL IMPAIRMENT

Retrieved on: 
Friday, April 5, 2024
Glaucoma, Partnership, Shoe, Macular degeneration, OPTIC, Visual impairment, Challenger, Artha

Optic 2000 is committed to supporting the development of technological innovation to help visually impaired people live independently.

Key Points: 
  • Optic 2000 is committed to supporting the development of technological innovation to help visually impaired people live independently.
  • This weekend, Optic 2000 and Artha launched the "Optic 2000 Challenger" challenge with Salim Ejnaïni, the first visually impaired player equipped with an Artha belt, taking on able-bodied players on the famous Trackmania game.
  • This major event was also an opportunity to raise public awareness of visual impairment and the risks of overexposure to screens.
  • The public could also enjoy an inclusive experience with a workshop designed to raise awareness of visual impairment: by wearing special glasses simulating visual problems (macular degeneration, glaucoma, etc.

OPTIC 2000 & AUSTRALIEGAD LAUNCHED AN ORIGINAL CHALLENGE AT THE GAMERS ASSEMBLY TO RAISE PUBLIC AWARENESS OF VISUAL IMPAIRMENT

Retrieved on: 
Friday, April 5, 2024
Glaucoma, Partnership, Shoe, Macular degeneration, OPTIC, Visual impairment, Challenger, Artha

Optic 2000 is committed to supporting the development of technological innovation to help visually impaired people live independently.

Key Points: 
  • Optic 2000 is committed to supporting the development of technological innovation to help visually impaired people live independently.
  • This weekend, Optic 2000 and Artha launched the "Optic 2000 Challenger" challenge with Salim Ejnaïni, the first visually impaired player equipped with an Artha belt, taking on able-bodied players on the famous Trackmania game.
  • This major event was also an opportunity to raise public awareness of visual impairment and the risks of overexposure to screens.
  • The public could also enjoy an inclusive experience with a workshop designed to raise awareness of visual impairment: by wearing special glasses simulating visual problems (macular degeneration, glaucoma, etc.

Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates

Retrieved on: 
Monday, March 18, 2024
Research, Adverum Biotechnologies, Vasculitis, Three Months, Macula, Chorioretinitis, Inflammation, Patient, Episcleritis, American Academy, Anti-VEGF, LUNA, Intraocular pressure, Investment, Clinical trial, Injection, Safety, Drug development, Paratriathlon, AMD, AAO, OPTIC, Retinitis, CST, Vascular occlusion, Annual general meeting, VEGF, Pharmaceutical industry

REDWOOD CITY, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today reported financial results for the fourth quarter and full year 2023. The company also provided recent pipeline highlights and corporate updates.

Key Points: 
  • The company also provided recent pipeline highlights and corporate updates.
  • 85% and 68% of patients at the 2E11 and 6E10 doses, respectively, received no supplemental injections through 26 weeks.
  • Stock-based compensation expense included in research and development expenses was $1.0 million for the fourth quarter of 2023.
  • Stock-based compensation expense included in general and administrative expenses was $3.1 million for the fourth quarter of 2023.

FSET Recognized on CRN's 2024 Security 100 List

Retrieved on: 
Friday, March 1, 2024
ISO, Managed services, CRN, MSP, The Channel Company, Growth, Information, OPTIC, Organization, RMS, SOC, Security, Risk management

KENORA, ON, March 1, 2024 /CNW/ - FSET Inc. announced today that for the second consecutive year, CRN ®, a brand of The Channel Company, has named FSET to its Managed Service Provider (MSP) 500 list in the Security 100 category for 2024.

Key Points: 
  • KENORA, ON, March 1, 2024 /CNW/ - FSET Inc. announced today that for the second consecutive year, CRN ®, a brand of The Channel Company, has named FSET to its Managed Service Provider (MSP) 500 list in the Security 100 category for 2024.
  • FSET's innovative managed services have again positioned the company as a leader in the IT security sector, distinguishing them as one of only two Canadian entities featured in the 2024 Security 100 list.
  • Of the three sections the annual MSP 500 list is divided into, FSET was included as a part of the Security 100, recognizing MSPs focused primarily on off-premises and cloud-based security services.
  • As an ISO 27001-certified company, FSET is proud to offer its clientele some of Canada's highest possible degrees of security.

Adverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline Highlights

Retrieved on: 
Thursday, November 9, 2023
Drug development, Three Months, Ophthalmology, Safety, Annual general meeting, Research, American Academy of Ophthalmology, Gene, Allergan, Investment, Anti-VEGF, American Academy, Data, Patient, Cell, LUNA, OPTIC, AAO, AMD, NHP, CMC, Injection, CST, Inflammation, Pharmaceutical industry, Dietary supplement, Medical imaging, Medical device, Cryptocurrency, Adverum Biotechnologies

REDWOOD CITY, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • “In our OPTIC presentation at AAO, we’ve built upon our industry leading dataset in wet AMD gene therapy,” stated Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies.
  • Scientific Meeting Presentations: In October 2023, Adverum showcased non-clinical data in two presentations at the European Society of Cell and Gene Therapy 2023 Annual Meeting.
  • Stock-based compensation expense included in research and development expenses was $1.2 million for the third quarter of 2023.
  • Stock-based compensation expense included in general and administrative expenses was $3.2 million for the third quarter of 2023.

Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023

Retrieved on: 
Saturday, November 4, 2023
Patient, CST, OPTIC, Adverum Biotechnologies, AMD, Data, AAO, Injection, Maintenance, Inflammation, Additive effect, Learning, IVT, American Academy, American Academy of Ophthalmology, Annual general meeting, Safety, Visual acuity, Anti-VEGF, Medical imaging, Birth control, Pharmaceutical industry, Dietary supplement

A summary of previously announced aflibercept protein levels from the LUNA study was also presented.

Key Points: 
  • A summary of previously announced aflibercept protein levels from the LUNA study was also presented.
  • “These efforts are now supported by the most mature dataset in wet AMD IVT gene therapy, with the OPTIC safety and efficacy data now sustained out to 3 years.
  • We are particularly encouraged by the continuous and consistent aflibercept protein levels observed at up to 4.5 years post-treatment.
  • Taken together, the efficacy and safety at the 2E11 dose in the OPTIC trial underscore Ixo-vec's potential as a promising treatment option for wet AMD patients addressing real-world unmet needs.

Adverum Biotechnologies Announces Positive Aflibercept Protein Level Data from the LUNA Phase 2 Trial

Retrieved on: 
Tuesday, September 26, 2023
Retina, Injection, Maintenance, Adverum Biotechnologies, Anti-VEGF, AAO, Life, Eye, ELISA, IVT, Choroid, Patient, Humour, M.A, Visual acuity, Safety, Pharmaceutical industry, Vaccine, Medical device, Dietary supplement, Medical imaging, OPTIC

REDWOOD CITY, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced initial aflibercept protein expression data from its ongoing Phase 2 LUNA trial evaluating ixoberogene soroparvovec (Ixo-vec) for the treatment of wet age-related macular degeneration (wet AMD). New data announced today include aflibercept protein levels for both the 2E11 and 6E10 vg/eye doses, suggesting that both doses are within the therapeutically active range. Notably, these protein expression levels are consistent with levels observed in the OPTIC trial, in which aflibercept levels and corresponding clinical activity have been sustained in patients through multiple years of follow-up after a single Ixo-vec injection.

Key Points: 
  • New data announced today include aflibercept protein levels for both the 2E11 and 6E10 vg/eye doses, suggesting that both doses are within the therapeutically active range.
  • “This first data cut from the LUNA trial is highly encouraging, showing similar aflibercept expression levels at the 2E11 and 6E10 doses,” stated Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies.
  • Aqueous Aflibercept Protein Expression Levels:
    Aflibercept protein data suggest Ixo-vec at the 2E11 and 6E10 doses deliver similar levels of aflibercept that are both within the therapeutically active range based on OPTIC and non-human primate data.
  • Presentation of OPTIC four-year Ixo-vec aflibercept protein expression data and three-year extension efficacy and safety data at the American Academy Ophthalmology (AAO) Meeting in November 2023.

Adverum Biotechnologies Completes Enrollment of Phase 2 LUNA Trial in Wet AMD and Reports Second Quarter 2023 Financial Results

Retrieved on: 
Thursday, August 10, 2023
Insurance, CFI, Partnership, Doctor of Pharmacy, Anticipation, Optogenetics, AMD, OPTIC, European Medicines Agency, Eye, Complement, Geographic atrophy, Research, LUNA, GA, Inflammation, AAV, PRIME, Messenger, IVT, Data, Patient, Complement factor I, Investment, Annual general meeting, United Kingdom, Diagnosis, NHP, United, Medicines and Healthcare products Regulatory Agency, Innovation, FDA, Safety, Three Months, Caregiver, Pharmaceutical industry, Vaccine, Medical device, Cryptocurrency, Adverum Biotechnologies

REDWOOD CITY, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today provided an update on its ongoing Phase 2 LUNA trial evaluating ixoberogene soroparvovec (Ixo-vec) for the treatment of wet age-related macular degeneration (wet AMD) and reported financial results for the second quarter ended June 30, 2023.

Key Points: 
  • “We are pleased to announce completion of enrollment in our Phase 2 LUNA trial,” stated Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies.
  • “The LUNA study design allows us to evaluate efficacy and safety of two Ixo-vec doses, while optimizing the prophylactic steroid regimens.
  • Stock-based compensation expense included in research and development expenses was $1.4 million for the second quarter of 2023.
  • Stock-based compensation expense included in general and administrative expenses was $3.1 million for the second quarter of 2023.

TEPEZZA® (teprotumumab) Approved in Brazil for the Treatment of Active Thyroid Eye Disease (TED)

Retrieved on: 
Monday, June 26, 2023
Science, Biotechnology, Research, Pharmaceutical, Optical, Health, FDA, Clinical Trials, Exophthalmos, ANVISA, OPTIC, Diplopia, Medicine, Patient, Autoimmune disease, CAS, Brazilian Health Regulatory Agency, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, TED

Horizon Therapeutics plc (Nasdaq: HZNP) today announced the Brazilian Health Regulatory Agency (ANVISA) has approved TEPEZZA for the treatment of active TED.

Key Points: 
  • Horizon Therapeutics plc (Nasdaq: HZNP) today announced the Brazilian Health Regulatory Agency (ANVISA) has approved TEPEZZA for the treatment of active TED.
  • TEPEZZA is the first and only medicine approved for active TED in Brazil, filling a significant unmet need for those who are living with this progressive autoimmune disease that can threaten vision.
  • The first trial in Japan (OPTIC-J) is evaluating TEPEZZA for the treatment of TED patients with disease duration of nine months or less and high clinical activity score (CAS), which is a measure of disease activity.
  • The second is evaluating TEPEZZA for the treatment of adults with disease duration of two to ten years and low CAS.

HALCON OPTIC Honored With Four Awards at NeoCon 2023

Retrieved on: 
Monday, June 19, 2023
Table, Exhibition, Education, Health, Sales, Hip, OPTIC, Interior Design (magazine), Acoustics, Collection, Interior, Neoconservatism, Interior design, Silver

STEWARTVILLE, Minn., June 19, 2023 (GLOBE NEWSWIRE) -- Today HALCON announced its new expansive collection of tables and storage, HALCON OPTIC™, was awarded Best of NeoCon Gold for conference room furniture, and Silver in furniture storage and integrated technology categories as well as an Interior Design HiP award at NeoCon 2023.

Key Points: 
  • STEWARTVILLE, Minn., June 19, 2023 (GLOBE NEWSWIRE) -- Today HALCON announced its new expansive collection of tables and storage, HALCON OPTIC™, was awarded Best of NeoCon Gold for conference room furniture, and Silver in furniture storage and integrated technology categories as well as an Interior Design HiP award at NeoCon 2023.
  • OPTIC is the latest solution in the furniture manufacturer’s extensive portfolio of private and open office and meeting room solutions.
  • “We are honored to again be recognized by the Best of NeoCon jurors and Interior Design Magazine,” said Ben Conway, president of HALCON.
  • A hallmark of the trade show since 1990, Best of NeoCon is the official awards program evaluating outstanding new products from exhibiting companies across a wide range of verticals.